Janney Montgomery Scott LLC Has $592,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Janney Montgomery Scott LLC grew its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 129.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,799 shares of the company's stock after buying an additional 4,972 shares during the quarter. Janney Montgomery Scott LLC's holdings in TransMedics Group were worth $592,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Braidwell LP acquired a new position in shares of TransMedics Group in the fourth quarter worth approximately $57,493,000. Norges Bank acquired a new stake in shares of TransMedics Group during the fourth quarter worth $22,861,000. Mackenzie Financial Corp raised its stake in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after buying an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after buying an additional 220,804 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Stock Down 1.9%

TransMedics Group stock opened at $127.69 on Thursday. The firm has a 50 day simple moving average of $120.93 and a 200 day simple moving average of $87.49. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of 93.89 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same quarter in the previous year, the company earned $0.35 earnings per share. TransMedics Group's revenue for the quarter was up 48.2% on a year-over-year basis. On average, analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on TMDX. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer increased their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $127.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.